Elaine R. Mardis, PhD, FAACR

Elaine R. Mardis, PhD, FAACR

Co-executive Director 
​The Institute for Genomic Medicine at Nationwide Children's Hospital 
Columbus, Ohio

Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is co-executive director of the Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio. She is also a professor of pediatrics and a member of the Solid Tumor Therapeutics Program, OSU Comprehensive Cancer Center, The Ohio State University College of Medicine in Columbus; and an adjunct professor in the Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, North Carolina.

Dr. Mardis’ research interests focus genomic characterization of cancer and its implications for cancer medicine. She was part of the team that reported the first next-generation-based sequencing of a whole cancer genome, and she has participated extensively in The Cancer Genome Atlas and the Pediatric Cancer Genome Project.

An active member of the AACR, Mardis was elected to the Board of Directors for the 2015-2018 term and served as President-Elect for 2018-2019. She is a senior editor of the AACR journal Molecular Cancer Research. Since 2015, she has been a member of the Project GENIE Advisory Board. She has also served as chair (2017) and cochair (2011-2013, 2015-2016) of the Annual Meeting Program Committee and on the Writing Committee (2013) and Steering Committee (2013-2014) for the AACR Cancer Progress Report.

Mardis has been on the faculty of the AACR’s Scientist↔Survivor Program and of the educational workshop “Translational Cancer Research for Basic Scientists.” She was a member of the Clinical and Translational Cancer Research Steering Committee (2012-2015); a member and cochair of the Precision Medicine Series “Drug Sensitivity and Response: Improving Cancer Therapy” (2013); a member of the Scientific Program Committee for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2013, 2014); a member of the Special Conferences Committee (2013-present); organizer of the Special Conference “Hematologic Malignancies: Translating Discoveries to Novel Therapies” (2014); member and cochair of the Precision Medicine Series “Integrating Clinical Genomics and Cancer Therapy” (2015); and a member of the Pezcoller Foundation-AACR International Award for Cancer Research Selection Committee (2017).

Dr. Mardis holds five U.S. patents, including a patient-specific, mutation-directed immunotherapy for cancer. She has co-authored more than 250 scientific articles in publications including CellJournal of Clinical OncologyBlood, and Cancer Epidemiology, Biomarkers & Prevention

Dr. Mardis graduated from the University of Oklahoma with a BS in zoology and completed her PhD in chemistry and biochemistry, also at Oklahoma. After earning her doctorate, she joined BioRad Laboratories as a senior research scientist. In 1993, she joined the faculty at Washington University School of Medicine, becoming codirector of the McDonnell Genome Institute in 2002 and the Robert E. and Louise F. Dunn Distinguished Professor of Medicine in 2014.